Amplification and deletion of the ACHE and BCHE cholinesterase genes in sporadic breast cancer

Cancer Genetics and Cytogenetics

Volumn 197, Issue 2, 2010, Pages 158-165

  Bernardi, Caroline C ^a   Ribeiro, Enilze de S F ^a   Cavalli, Iglenir J ^a   Chautard Freire Maia, Eleidi A ^a   Souza, Ricardo L R ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE DELETION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ORAL CONTRACEPTION; PRIORITY JOURNAL; PROTO ONCOGENE; REAL TIME POLYMERASE CHAIN REACTION; TUMOR VOLUME;

ACETYLCHOLINESTERASE; BREAST NEOPLASMS; BUTYRYLCHOLINESTERASE; DATA INTERPRETATION, STATISTICAL; FEMALE; GENE AMPLIFICATION; GENE DELETION; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2;

EID: 77249143987     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2009.10.011     Document Type: Article

References (70)

1. Allderdice P.W., Gardner H.A.R., Galutira D., Lockridge O., La Du B.N., and McAlpine P.J. The cloned butyrylcholinesterase (BCHE) gene maps to a single chromosome site, 3q26. Genomics 11 (1991) 452-454
2. Getman D.K., Eubanks J.H., Camp S., Evans G.A., and Taylor P. The human gene encoding acetylcholinesterase is located on the long arm of chromosome 7. Am J Hum Genet 51 (1992) 170-177
3. Galenko-Yaroshevskii A.P., Derlugov L.P., Ponomarev V.V., and Dukhanin A.S. Pharmacokinetics and pharmacodynamics of a new local anesthetic agent. Bull Exp Biol Med 136 (2003) 170-173
4. Lockridge O., Mottershaw-Jackson N., Eckerson H., and La Du B.N. Hydrolysis of diacetylmorphine (heroin) by human serum cholinesterase. J Pharmacol Exp Ther 215 (1980) 1-8
5. Carmona G.N., Jufer R.A., Goldberg S.R., Gorelick D.A., Greig N.H., Yu Q., Cone E.J., and Schindler C.W. Butyrylcholinesterase accelerates cocaine metabolism: in vitro and in vivo effects in nonhuman primates and humans. Drug Metab Dispos 28 (2000) 367-371
6. Masson P., Froment M.T., Fortier P.L., Visicchio J.E., Bartels C.F., and Lockridge O. Butyrylcholinesterase-catalysed hydrolysis of aspirin, a negatively charged ester, and aspirin-related neutral esters. Biochim Biophys Acta 387 (1998) 41-52
7. Patocka J., Kuca K., and Jun D. Acetylcholinesterase and butyrylcholinesterase-important enzymes of human body. Acta Med 47 (2004) 215-228
8. Bigbee J.W., Sharma K.V., Gupta J.J., and Dupree J.L. Morphogenic role for acetylcholinesterase in axonal outgrowth during neural development. Environ Health Perspect 107 Suppl. 1 (1999) 81-87
9. Darvesh S., Hopkins D.A., and Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 4 (2003) 131-138
10. Bytyqi A.H., Lockridge O., Duysen E., Wang Y., Wolfrum U., and Layer P.G. Impaired formation of the inner retina in an AChE knockout mouse results in degeneration of all photoreceptors. Eur J Neurosci 20 (2004) 2953-2962
11. Betz H., Bourgeois J.P., and Changeux J.P. Evolution of cholinergic proteins in developing slow and fast skeletal muscles in chick embryo. J Physiol 302 (1980) 197-218
12. Stephenson J., Czepulkowski B., Hirst W., and Mufti G.J. Deletion of the acetylcholinesterase locus at 7q22 associated with myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML). Leuk Res 20 (1996) 235-241
13. Layer P.G. Cholinesterases during development of the avian nervous system. Cell Mol Neurobiol 11 (1991) 7-33
14. Ben Aziz-Aloya R., Sternfeld M., and Soreq H. Promoter elements and alternative splicing in the human ACHE gene. Prog Brain Res 98 (1993) 147-153
15. Layer P.G., and Willbold E. Novel functions of cholinesterases in development, physiology and disease. Prog Histochem Cytochem 29 (1995) 1-94
16. Montenegro M.F., Nieto-Cerón S., Ruiz-Espejo F., Páez de la Cadena M., Rodríguez-Berrocal F.J., and Vidal C.J. Cholinesterase activity and enzyme components in healthy and cancerous human colorectal sections. Chem Biol Interact 15 (2005) 429-430
17. Martínez-Moreno P., Nieto-Cerón S., Torres-Lanzas J., Ruiz-Espejo F., Tovar-Zapata I., Martínez-Hernández P., Rodríguez-López J.N., Vidal C.J., and Cabezas-Herrera J. Cholinesterase activity of human lung tumours varies according to their histological classification. Carcinogenesis 27 (2006) 429-436
18. Perry C., Sklan E.H., Birikh K., Shapira M., Trejo L., Eldor A., and Soreq H. Complex regulation of acetylcholinesterase gene expression in human brain tumors. Oncogene 21 (2002) 8428-8441
19. Vidal C.J. Expression of cholinesterases in brain and non-brain tumours. Chem Biol Interact 15 (2005) 227-232
20. Zakut H., Ehrlich G., Ayalon A., Prody C.A., Malinger G., Seidman S., Ginzberg D., Kehlenbach R., and Soreq H. Acetylcholinesterase and butyrylcholinesterase genes coamplify in primary ovarian carcinomas. J Clin Invest 86 (1990) 900-908
21. Lapidot-Lifson Y., Prody C.A., Ginzberg D., Meytes D., Zakut H., and Soreq H. Coamplification of human acetylcholinesterase and butyrylcholinesterase genes in blood cells: correlation with various leukemias and abnormal megakaryocytopoiesis. Proc Natl Acad Sci U S A 86 (1989) 4715-4719
22. Brass N., Racz A., Heckel D., Remberger K., Sybrecht G.W., and Meese E.U. Amplification of the genes BCHE and SLC2A2 in 40% of squamous cell carcinoma of the lung. Cancer Res 57 (1997) 2290-2294
23. Hibi K., Trink B., Patturajan M., Westra W.H., Caballero O.L., Hill D.E., Ratovitski E.A., Jen J., and Sidransky D. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A 97 (2000) 5462-5467
24. Yokoi S., Yasui K., Iizasa T., Imoto I., Fujisawa T., and Inazawa J. TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers. Clin Cancer Res 9 (2003) 4705-4713
25. Jung V., Kindich R., Kamradt J., Jung M., Müller M., Schulz W.A., Engers R., Unteregger G., Stöckle M., Zimmermann R., and Wullich B. Genomic and expression analysis of the 3q25-q26 amplification unit reveals TLOC1/SEC62 as a probable target gene in prostate cancer. Mol Cancer Res 4 (2006) 169-176
26. Marsh D.J., Theodosopoulos G., Martin-Schulte K., Richardson A.L., Philips J., Roher H.D., Delbridge L., and Robinson B.G. Genome-wide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 88 (2003) 1866-1872
27. Ruiz-Espejo F., Cabezas-Herrera J., Illana J., Campoy F.J., and Vidal C.J. Cholinesterase activity and acetylcholinesterase glycosylation are altered in human breast cancer. Breast Cancer Res Treat 72 (2002) 11-22
28. Ruiz-Espejo F., Cabezas-Herrera J., Illana J., Campoy F.J., Muñoz-Delgado E., and Vidal C.J. Breast cancer metastasis alters acetylcholinesterase activity and the composition of enzyme forms in axillary lymph nodes. Breast Cancer Res Treat 80 (2003) 105-114
29. Buerger H., Otterbach F., Simon R., Schäfer K.L., Poremba C., Diallo R., Brinkschmidt C., Dockhorn-Dworniczak B., and Boecker W. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol 189 (1999) 521-526
30. Forozan F., Mahlamäki E.H., Monni O., Chen Y., Veldman R., Jiang Y., Gooden G.C., Ethier S.P., Kallioniemi A., and Kallioniemi O.P. Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. Cancer Res 60 (2000) 4519-4525
31. Burdall S.E., Hanby A.M., Lansdown M.R., and Speirs V. Breast cancer cell lines: friend or foe?. Breast Cancer Res 5 (2003) 89-95
32. Pinto A.E., Roque L., Rodrigues R., André S., and Soares J. Frequent 7q gains in flow cytometric multiploid/hypertetraploid breast carcinomas: a study of chromosome imbalances by comparative genomic hybridisation. J Clin Pathol 59 (2006) 367-372
33. Lu Y.J., Birdsall S., Osin P., Gusterson B., and Shipley J. Phyllodes tumors of the breast analyzed by comparative genomic hybridization and association of increased 1q copy number with stromal overgrowth and recurrence. Genes Chromosomes Cancer 20 (1997) 275-281
34. Cayre A., Mishellany F., Lagarde N., and Penault-Llorca F. Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification. Breast Cancer Res 9 (2007) R64
35. Sambrook J., Fritsch E.F., and Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. (1989), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
36. Bignon J.D., and Fernández-Viña M.A. Protocols of the 12th International Histocompatibility workshop for typing of HLA class II alleles by DNA amplifications by the polymerase chain reaction (PCR) and hybridization with sequence specific oligonucleotide probes (SSOP). In: Charron D. (Ed). Genetic diversity of HLA: functional and medical implication (1997), Sevres: EDK, Paris 584-595
37. Schmittgen T.D., and Zakrajsek B.A. Effect of experimental treatment on housekeeping gene expression: validation by real-time, quantitative RT-PCR. J Biochem Biophys Methods 46 (2000) 69-81
38. Dorak MT, editor. Real-time PCR [Internet]. 2006. Accessed Dec. 12, 2007. Available at: http://www.dorak.info/genetics/realtime.html. Accessed on 12 December, 2007.
39. Larionov A., Krause A., and Miller W. A standard curve based method for relative real time PCR data processing. BMC Bioinformatics 6 (2005) 62
40. Applied Biosystems. Guide to performing relative quantitation of gene expression using real-time quantitative PCR (2004), Applied Biosystems, Foster City, CA
41. Königshoff M., Wilhelm J., Bohle R.M., Pingoud A., and Hahn M. HER-2/neu gene copy number quantified by real-time PCR: comparison of gene amplification, heterozygosity, and immunohistochemical status in breast cancer tissue. Clin Chem 49 (2003) 219-229
42. Novais CM, Pires-Alves M, Silva FF. Real-time PCR [PCR em tempo real. In Portuguese]. Rev Biotecnolog Desenv 33:10-13.
43. Bustin S.A., and Nolan T. Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction. J Biomol Tech 15 (2004) 155-166
44. Hodgson S.V., and Evans G. The inherited basis of cancer. In: Foulkes W.D., and Hodgson S.V. (Eds). Inherited susceptibility to cancer: clinical, predictive and ethical perspectives (1998), Cambridge University Press, New York 3-19
45. Wren B.G. The origin of breast cancer. Menopause 14 (2007) 1060-1068
46. Schimke R.T., Brown P.C., and Kaufman R.J. Gene amplification and drug resistance in mammalian cells. Natl Cancer Inst Monogr 60 (1982) 79-86
47. Soreq H., and Zakut H. Amplification of butyrylcholinesterase and acetylcholinesterase genes in normal and tumor tissues: putative relationship to organophosphorous poisoning. Pharm Res 7 (1990) 1-7
48. Kawato Y., Sekiguchi M., Akahane K., Tsutomi Y., Hirota Y., Kuga H., Suzuki W., Hakusui H., and Sato K. Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats. J Pharm Pharmacol 45 (1993) 444-448
49. O'Driscoll L., and Clynes M. Molecular markers of multiple drug resistance in breast cancer. Chemotherapy 52 (2006) 125-129
50. Song P., Sekhon H.S., Jia Y., Keller J.A., Blusztajn J.K., Mark G.P., and Spindel E.R. Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma. Cancer Res 63 (2003) 214-221
51. Cabello G., Valenzuela M., Vilaxa A., Durán V., Rudolph I., Hrepic N., and Calaf G. A rat mammary tumor model induced by the organophosphorous pesticides parathion and malathion, possibly through acetylcholinesterase inhibition. Environ Health Perspect 109 (2001) 471-479
52. Shayesteh L., Lu Y., Kuo W.L., Baldocchi R., Godfrey T., Collins C., Pinkel D., Powell B., Mills G.B., and Gray J.W. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21 (1999) 99-102
53. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., Willson J.K., Markowitz S., Kinzler K.W., Vogelstein B., and Velculescu V.E. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (2004) 554
54. Takai S., Long J.E., Yamada K., and Miki T. Chromosomal localization of the human ECT2 proto-oncogene to 3q26.1-q26.2 by somatic cell analysis and fluorescence in situ hybridization. Genomics 27 (1995) 220-222
55. Nanjundan M., Nakayama Y., Cheng K.W., Lahad J., Liu J., Lu K., Kuo W.L., Smith-Mccune K., Fishman D., Gray J.W., and Mills G.B. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res 67 (2007) 3074-3084
56. Dean M., Park M., Le Beau M.M., Robins T.S., Diaz M.O., Rowley J.D., Blair D.G., and Vande Woude G.F. The human met oncogene is related to the tyrosine kinase oncogenes. Nature 318 (1985) 385-388
57. Zenklusen J.C., Conti C.J., and Green E.D. Mutational and functional analyses that ST7 is a highly conserved tumor-supressor gene on human chromosome 7q31. Nat Genet 27 (2001) 392-398
58. Pierga J.Y., Reis-Filho J.S., Cleator S.J., Dexter T., Mackay A., Simpson P., Fenwick K., Iravani M., Salter J., Hills M., Jones C., Ashworth A., Smith I.E., Powles T., and Dowsett M. Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy. Br J Cancer 96 (2007) 341-351
59. Tonon G., Wong K., Maulik G., Brennan C., Feng B., Zhang Y., Khatry D.B., Protopopov A., You M.J., Aguirre A.J., Martin E.S., Yang Z., Ji H., Chin L., and Depinho R.A. High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A 102 (2005) 9625-9630
60. Chiuri V.E., Leo G., and Lorusso V. Clinical and therapeutic perspectives of gene expression profiling for breast cancer. Ann Oncol 18 Suppl. 6 (2007) 58-62 vi
61. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the ERBB2-2/neu oncogene. Science 235 (1987) 177-182
62. Bogliolo L. Bogliolo patologia. 7th ed. (2006), Guanabara Koogan, Rio de Janeiro pp. 637-8
63. Vanden Bempt I., Drijkoningen M., and De Wolf-Peeters C. The complexity of genotypic alterations underlying ERBB2-positive breast cancer: an explanation for its clinical heterogeneity. Curr Opin Oncol 19 (2007) 552-557
64. Han H.J., Russo J., Kohwi Y., and Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature 452 (2008) 187-193
65. Ellsworth R.E., Ellsworth D.L., Love B., Patney H.L., Hoffman L.R., Kane J., Hooke J.A., and Shriver C.D. Correlation of levels and patterns of genomic instability with histological grading of DCIS. Ann Surg Oncol 14 (2007) 3070-3077
66. Ellsworth R.E., Hooke J.A., Love B., Kane J.L., Patney H.L., Ellsworth D.L., and Shriver C.D. Correlation of levels and patterns of genomic instability with histological grading of invasive breast tumors. Breast Cancer Res Treat 107 (2008) 259-265
67. Duffy S.W., Tabar L., Fagerberg G., Gad A., Gröntoft O., South M.C., and Day N.E. Breast screening, prognostic factors and survival: results from the Swedish two county study. Br J Cancer 64 (1991) 1133-1138
68. Meyer J.S., Fahrner M., and Daniel F.C. Pathology and behavior of small breast carcinomas. Semin Diagn Pathol 16 (1999) 257-268
69. Schönborn I., Nischan P., and Ebeling K. Oral contraceptive use and the prognosis of breast cancer. Breast Cancer Res Treat 30 (1994) 283-292
70. Largent J.A., Ziogas A., and Anton-Culver H. Effect of reproductive factors on stage, grade and hormone receptor status in early-onset breast cancer. Breast Cancer Res 7 (2005) R541-R554